{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:40:37Z","timestamp":1781264437255,"version":"3.54.1"},"reference-count":2,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.jinf.2005.08.026","type":"journal-article","created":{"date-parts":[[2005,10,21]],"date-time":"2005-10-21T07:13:38Z","timestamp":1129878818000},"page":"e189-e190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Can boosted atazanavir induce hyperlipotrophy?"],"prefix":"10.1016","volume":"52","author":[{"given":"P.","family":"Dellamonica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2005.08.026_bib1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1086\/420932","article-title":"Atazanavir: new option for treatment of HIV infection","volume":"38","author":"Havlir","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2005.08.026_bib2","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","article-title":"Interactions between atazanavir\u2013ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients","volume":"48","author":"Taburet","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445305002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445305002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:30:05Z","timestamp":1758987005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445305002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":2,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0163445305002525"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2005.08.026","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can boosted atazanavir induce hyperlipotrophy?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2005.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}